 |
The 130th Annual Meeting of APHA |
|
The 130th Annual Meeting of APHA |
2009.0: Sunday, November 10, 2002: 8:00 AM-11:30 AM | |||
Oral | |||
| |||
| Statement of Purpose and Institute Overview: | |||
| This institute will describe the history of drug regulation in the United States. It will introduce participants to the economics of the pharmaceutical industry, including a discussion of the costs of drug development and an analysis of drug pricing. comparisons between the United States and other nations will be delineated. Industry profits, business trends, and the results of lobbying will be examined, as well as ongoing litigation. Data on the costs, effectiveness and truthfulness of direct-to-provider and direct-to-consumer advertising will be evaluated. Given the dramatic increase over the last few decades in the number of over-the-counter medications and the use of so-called alternative medicines, the health benefits and risks of these products will be described briefly. Particular attention will be paid to issues relevant to the public health community, including compensation to indigenous peoples for biological knowledge and plant materials, overuse of agricultural antibiotics and its effects on human disease, the increasing costs of medications for seniors, and the lack of availability of drugs to combat AIDS and other major infectious diseases in the underdeveloped world. Finally, ethical issues relevant to drug company research and the increasing links between academia and industry will be explored. Adequate time will be provided to discuss controversial issues. | |||
| Learning Objectives: Participants will hopefully gain greater insight in to how drugs are developed, marketed, and regulated, and how they can work through governmental and non-governmental agencies to increase funding for tropical diseases and access to life-saving medications for patients in both the developed and developing worlds. They should also be better able to analyze the influence of the drug industry on government and academia; to improve collaborative efforts to develop and distribute medications against human disease; to work to decrease overuse of agricultural antibiotics; and to uphold ethical, professional behavior in contacts between themselves (and their institutions) and drug company representatives. | |||
| See individual abstracts for presenting author's disclosure statement and author's information. | |||
| Martin T. Donahoe, MD FACP | |||
| A History of Drug Development in the United States Martin T. Donahoe, MD FACP | |||
| Drug Classifications: Prescription Only, Over-the-counter, Generic, and "Alternative" Medications Martin T. Donahoe, MD FACP | |||
| Economics of the Pharmaceutical Industry Martin T. Donahoe, MD FACP | |||
| Group Discussion / Q & A | |||
| Break | |||
| Pharmaceuticals and Special Populations Martin T. Donahoe, MD FACP | |||
| Factory Farming, Agricultural Antibiotics, and Drug-resistant Human Infections Martin T. Donahoe, MD FACP | |||
| Pharmaceutical Company Advertising Martin T. Donahoe, MD FACP | |||
| Group Discussion / Q & A | |||
| Effects of Pharmaceutical Industry/Academia Collaboration Martin T. Donahoe, MD FACP | |||
| Group Discussion / Q & A | |||
| Concluding Remarks | |||
| Close | |||
| Organized by: | APHA-Continuing Education Institutes | ||
| CE Credits: | CME, Health Education (CHES), Nursing, Pharmacy, Social Work | ||